Coegin Pharma AB
NNGM:COEGIN2.13
SEK
+0.06
(+2.90%)
ISIN
SE0020357754
Return %
Stock
S&P 500
1Y
-66.08
14.20
3Y
-62.50
81.12
5Y
-93.76
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jens Eriksson
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lund Sweden
- IPO Date
- Feb 21, 2018
- Website
- coeginpharma.com
- Similar Companies
- Business
- Coegin Pharma AB is a Swedish commercial-stage biotechnology and dermocosmetics company that develops, manufactures, and commercializes science-based peptide technologies for hair and skin care. Founded in 2005 and headquartered in Lund, Sweden, the company operates within the cosmeceutical, aesthetic dermatology, and beauty longevity sectors, serving direct-to-consumer markets, specialized beauty retailers, dermatology and hair transplant clinics, and international distributor networks. Coegin Pharma AB structures its business around a dual-track commercial model combining proprietary brand commercialization and third-party distribution partnerships; its systematic product and technology portfolio comprises: Follicopeptide®, a patented biomimetic peptide complex designed to stimulate hair follicle growth, increase hair density, and counter thinning; VEXIENNE® Hair Active X™, a high-performance consumer scalp serum formulated with Follicopeptide® to support follicle vitality; Follicopeptide® Gel Serum, a specialized formulation for localized scalp application; VEXIENNE® Clinic, a professional-grade hair restoration product line engineered for post-transplant care and clinical hair preservation treatments; proprietary peptide-based eyelash and eyebrow enhancement serums; and NPP-4, a next-generation cosmetic peptide platform under development to promote natural skin pigmentation and even skin tone without ultraviolet radiation exposure. The company maintains research and administrative operations in Lund, Sweden, runs an agile production and formulation facility in Denmark to maintain supply chain and quality control, and distributes its product lines across Sweden, Norway, Denmark, Finland, and wider European markets. In recent years, Coegin Pharma AB executed a comprehensive strategic shift from clinical-stage pharmaceutical development to a commercial dermocosmetics enterprise, refocusing capital and resources on the commercialization of its proprietary peptide assets. In line with this commercial expansion, the company launched its proprietary consumer brand VEXIENNE® and entered key retail and international distribution agreements, including partnerships with Nordic beauty retailer LYKO, Swedish premium grooming retailer Gents, and Polish pharmaceutical distributor Mercapharm for regional commercialization under the Trichobalance brand. Operationally and financially, Coegin Pharma AB expanded its European investor base through a dual listing of its shares on Börse Stuttgart alongside its primary listing on the NGM Nordic SME exchange, established dedicated in-house production capabilities in Denmark, and advanced clinical assessments for its expanded portfolio of eyelash, eyebrow, and professional clinic applications.